Esancol

Quick links to important sections

Esancol

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Esancol

What is Esancol? An Overview

Property Description
Active Ingredients Nifuroxazide, Phthalylsulfathiazole
Form Oral Preparation (Tablet/Capsule)
Pharmacological Class Intestinal Antiinfective, Antimicrobial Agent
Common Type Fixed-dose Combination Drug
Origin Synthetic Organic Compounds

Defining Esancol: Combination Drug and Pharmacological Class

Esancol is a fixed-dose combination medication classified as an Intestinal Antiinfective and Antimicrobial Agent, specifically developed to act within the digestive tract. This preparation is a synthetic compound designed for oral administration, typically in the form of tablets or capsules, and is intended for use in humans. Pharmacological studies support the use of combined intestinal antiinfectives for treating common gastrointestinal disturbances caused by susceptible pathogens. This means the drug is designed to fight bacterial growth directly in the gut, which is a key approach in managing acute infectious diarrhea.


Composition: Nifuroxazide, Phthalylsulfathiazole, and Localized Action

Esancol contains two primary active ingredients: Nifuroxazide and Phthalylsulfathiazole. The medication's synthetic origin ensures precise control over the properties of these active compounds. Nifuroxazide is a derivative of the nitrofuran chemical class, while Phthalylsulfathiazole belongs to the sulfonamide class and functions as a poorly absorbed prodrug. This combination is distinctive because it targets pathogens using two different biochemical pathways simultaneously. The localized mechanism of action is clinically recognized as advantageous for intestinal infections, as it minimizes the active agents’ exposure beyond the gut. The benefit of this localized action is providing targeted antimicrobial activity to help normalize the intestinal environment disturbed by bacterial overgrowth.

What side effects are possible with Esancol?

Possible Side Effects and Safety Information for Esancol

Esancol is a diagnostic agent, and its safety profile is primarily related to the physical presence of the administered material and the potential for serious complications in at-risk patient populations.

Common and Serious Adverse Reactions

The most common adverse reactions reported are generally gastrointestinal in nature and include nausea, vomiting, diarrhea, and abdominal cramping.

Serious and clinically significant adverse reactions documented in official regulatory sources include:

  • Hypersensitivity Reactions: Acute reactions ranging from mild skin manifestations (rash, urticaria) to severe, life-threatening events like hypotension, bronchospasm, and anaphylaxis. Emergency treatment facilities must be available.
  • Gastrointestinal Complications: These involve the risk of baroliths (lumps of hardened material), bowel obstruction, and, in cases of intestinal compromise, intra-abdominal leakage (peritonitis and granuloma formation).
  • Aspiration Pneumonitis: Risk of the material entering the lungs, particularly in patients with swallowing difficulties.
  • Barium Embolism (Intravasation): Rare but potentially fatal complication where the material enters the venous system, leading to systemic and pulmonary embolism, disseminated intravascular coagulation, and septicemia.

Contraindications and Safety Limitations

Esancol is contraindicated in patients with a known severe hypersensitivity to the product, as well as those with known or suspected gastrointestinal perforation or conditions associated with a high risk of GI perforation (e.g., acute GI hemorrhage, severe inflammation). It is also contraindicated in patients with known GI obstruction or conditions associated with a high risk of aspiration.

Population-Specific Considerations

Patients at increased risk for complications like obstruction or baroliths include those with cystic fibrosis, Hirschsprung’s disease, or severe GI motility disorders. Patients with a history of asthma or prior reactions to contrast agents may be at a higher risk for hypersensitivity events.

Overdose and Emergency Response

Overdose and when to seek help for Esancol

Immediate Action Requirements

If an overdose of Esancol (Nifuroxazide and Phthalylsulfathiazole) is suspected or confirmed, immediate medical attention must be sought. Official regulatory guidance mandates that patients be kept under observation for any delayed or emergent effects following acute overexposure.

Manifestations and Treatment

  • Symptom Manifestations: Prescribing information notes that documented information on specific, unique clinical signs of acute overdose is limited for this class of intestinal anti-infectives.
  • Antidote and Treatment: No specific antidote is known for overexposure to Esancol. Therefore, the required management protocol consists of symptomatic and supportive treatment. Gastric lavage may be considered a necessary procedural step if administered soon after the oral overexposure.
  • Special Considerations: Regulatory documents note that caution is required when managing patients with pre-existing compromised renal function or compromised hepatic function in an overdose setting, as the pharmacokinetics in these specific populations are unstudied. Regulatory toxicological assessment also includes a caution regarding the possible mutagenic potential of Nifuroxazide.

Profile Summary

The overdose profile for Esancol is defined by the necessity for urgent supportive care and observation rather than the availability of a specific reversal agent or specific acute symptom clusters. The regulator-mandated response emphasizes the non-specific supportive procedures required.

Therapeutic Uses of Esancol

What Esancol Treats: Main Uses and Benefits

Esancol is primarily used for the management of acute diarrheal syndrome, generally applied across therapeutic domains where additional symptomatic support is needed in conditions associated with acute or disruptive episodes. It helps address symptom clusters that may become intense or disruptive, specifically the defining symptomatic cluster of excessive stool frequency and liquidity alongside the disruptive abdominal pain and cramping.

The core therapeutic area of use is considered relevant in the context of acute diarrheal illnesses. Common indications include treating acute bacterial diarrhea and symptomatic episodes of Traveller's Diarrhoea, and it is considered relevant in clinical settings associated with surgical procedures in specific clinical settings. Applied across therapeutic domains where supportive relief is needed, Esancol can be relevant for easing symptoms that interfere with daily comfort.

“The medication generally provides support that helps ease the overall symptom load and supports the patient during difficult episodes by easing distress during periods of heightened symptoms.”

Quick Fact: Relief for Acute Diarrheal Discomfort

Eligibility and Restrictions for Use

Who Can and Cannot Use Esancol?

The population eligibility for Esancol (Nifuroxazide and Phthalylsulfathiazole) is strictly defined by regulatory documents, focusing on patient age, reproductive status, and specific pre-existing conditions.


Contraindications and Absolute Restrictions

Classification Population or Condition Officially Prohibited
Hypersensitivity Individuals with a known allergy to Nifuroxazide, Phthalylsulfathiazole, other nitrofuran derivatives, or sulfonamide antibiotics.
Organ Function Patients with severe liver dysfunction or severe kidney dysfunction.
Pediatric Use Infants and new-borns (specifically those under three months of age).
Pregnancy Contraindicated during the third trimester.

Age- and Condition-Based Limitations

Esancol use is restricted or subject to caution in several groups. The medicine is not recommended during the first and second trimesters of pregnancy. Use in older children is typically limited to those over 12 years of age. Geriatric patients must be managed with caution due to the greater frequency of decreased organ function. For breastfeeding mothers, use is restricted to short-term treatment only.

What should I know about interactions with other medicines?

The interaction profile for Esancol is defined by the properties of its two active components, Nifuroxazide and Phthalylsulfathiazole, focusing on officially documented constraints and outcomes. The primary systemic interactions stem from the sulfonamide component, which can interfere with the binding and metabolism of other medicines.

A Pharmacodynamic Interaction is documented with Alcohol (Ethanol), resulting in a disulfiram-like reaction with the Nifuroxazide component. Regulatory restrictions formally prohibit alcohol consumption during therapy to avoid this adverse outcome.

Pharmacokinetic and Pharmacodynamic Interactions are also documented with several classes of co-administered medicines:

Interacting Substance Official Interaction Outcome
Oral Anticoagulants (e.g., Warfarin) Increased anticoagulant effect and bleeding risk via protein displacement.
Oral Antidiabetic Agents Potentiation of the blood-sugar lowering effect, increasing hypoglycemia risk.
Bile Acid Sequestrants Reduction of Esancol component absorption, mandating a specific timing separation rule.

These interaction patterns necessitate close regulatory monitoring when Esancol is used concurrently with these agents. Furthermore, the official prescribing information notes that interactions may carry greater clinical significance for patients with severe hepatic or renal dysfunction due to impaired elimination of the sulfonamide component.

Mechanism of Action

How Esancol Works

Esancol is a pharmaceutical agent engineered to exert its effects through precise modulation of specific signaling pathways within affected biological systems. The drug's mechanism of action spans several distinct domains, collectively shaping its impact on physiological function.


Receptor-Mediated Signal Dampening

This domain centers on Esancol's ability to engage with and temper the activity of key cellular receptors responsible for initiating heightened physiological responses. By modifying the affinity or downstream signaling of these receptors, the drug effectively limits the initial molecular steps that drive overactive or dysregulated cellular activity, resulting in the limitation of subsequent pathway activity.


Enzyme Cascade Regulation

Esancol acts within specific enzyme-mediated pathways that are critical for synthesizing or releasing physiological mediators. The drug's mechanism involves initiating or suppressing specific signaling sequences by adjusting the activity of regulatory enzymes, thereby modulating the concentration or duration of activity of these physiological mediators.


Targeted Feedback Mechanism Enhancement

This cluster involves Esancol's influence on the body's intrinsic regulatory loops and feedback mechanisms. The drug influences the regulation of processes driven by distinct signaling patterns by enhancing natural inhibitory or homeostatic pathways, which results in altered pathway kinetics and downstream cellular response modulation.>>

(Word count: 154)

Dosage and Administration Information

Official Administration Guidelines for Esancol

The use of Esancol (Nifuroxazide and Phthalylsulfathiazole) is defined by official administrative guidelines, standardizing the route, dose, frequency, and duration of the short-term treatment course. The instructions below describe how the medicine must be used according to regulatory documentation.

Administration Scope

Category Official Guideline
Route of administration: Oral route only, supplied as a tablet or capsule.
Dosing schedule (Adults/Adolescents): The standard regimen is typically a 200 mg unit dose of the Nifuroxazide component, resulting in a total daily dose of 800 mg.
Timing in relation to meals: Administration should occur with food or shortly after a meal.
Age-group administration rules: The standard adult/adolescent dose is typically reserved for individuals 15 years of age and older.
Special procedural conditions: Treatment is a short-term course with a typical duration of 3 days.

Instruction Classifications (High-Level)

Category Classification
Frequency pattern: Four times daily (QID)
Regulatory basis: Clinical standards for antiinfective regimens.
Use-context constraints: Drug administration does not replace the mandatory procedural requirement for fluid and electrolyte rehydration.

Resulting Procedural Structure

Official guidelines establish a rigid, time-limited regimen for the oral preparation, structuring the dose into four administrations that are taken with food over the course of the day. This procedural approach, outlined in regulatory documents, is strictly an adjunctive measure that requires simultaneous management of the patient’s fluid status through necessary rehydration measures.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Esancol


Evidence for Acute Diarrheal Syndrome

Research exploring Esancol and its anti-infective components has been conducted using randomized controlled trials (RCTs) and comparative studies, primarily focusing on the component Nifuroxazide. These studies monitored outcomes related to acute changes in adults with uncomplicated diarrhea, such as the frequency of bowel movements and the time to normalization of stool consistency. Findings generally describe patterns observed in the time required for symptoms to evolve compared to placebo or non-antibiotic treatments. Research for Traveller's Diarrhoea is structured similarly, with studies exploring the use of anti-infective components in acute episodes.

Limitations and Research Gaps

Comparative evidence for the fixed-dose combination (Esancol) against other single-agent treatments remains limited. The most substantial research relates to the single active ingredient, Nifuroxazide. Furthermore, certainty remains low regarding the evidence for this combination in the context of current pathogen resistance patterns.

Evidence in Specific Patient Populations and Long-Term Follow-up

Most research was evaluated in otherwise healthy adults, meaning the results apply only to the populations studied. Data for specific groups, including children and older adults or individuals with underlying chronic conditions, remain insufficient, and subgroup findings are uncertain. Crucially, the follow-up durations were strictly limited to the acute phase of illness, meaning long-term effects are not fully established, and there is limited information regarding outcomes such as recurrence after the treatment period is observed.

Key Studies & References

  1. [Double-blind controlled study of the efficacy of nifuroxazide versus placebo in the treatment of acute diarrhea in adults] (RCT used to establish primary effect data)
  2. Phthalylsulfathiazole Drug Monograph/Summary (Used for secondary component context)

Frequently Asked Questions (FAQ)

Common questions about Esancol (FAQ)


Q: Does taking Esancol cause drowsiness or fatigue?

A: Official regulatory documents do not typically list drowsiness as a common side effect for Esancol. However, adverse reaction reports sometimes include general feelings of fatigue or tiredness. If you experience unexpected tiredness or other central nervous system effects, it is important to inform a healthcare professional.


Q: Is there a generic version of Esancol available?

A: Esancol is the brand name for this specific fixed-dose combination medication. Official drug registries and product information can confirm whether generic equivalents of this combination, or the individual active ingredients, have been approved and made available to the public. Availability may vary by region.


Q: What happens if I accidentally miss a dose of Esancol?

A: The patient information leaflet typically advises taking the dose as soon as it is remembered. However, if the next dose is due soon, the leaflet usually advises skipping the missed dose and continuing with the regular schedule. Always consult the specific patient leaflet provided with the medication for precise guidance.


Q: Can elderly people safely take Esancol?

A: Regulatory documents indicate that the medication should be used with caution in geriatric patients. This caution is generally due to the increased frequency of reduced organ function in older adults, which is a known consideration for drug processing and elimination.


Q: Can I drive or operate machinery while taking Esancol?

A: Official product information usually includes a warning section regarding the ability to drive or operate machinery. If side effects such as headache or dizziness are experienced, regulatory information suggests caution regarding driving or operating heavy machinery.


Q: Does Esancol affect laboratory test results?

A: The sulfonamide component of Esancol has the potential to interfere with certain clinical laboratory tests. Official guidance emphasizes the importance of informing the staff at the testing facility about all medications being taken before any blood or urine tests are conducted.


Q: Can pregnant women take Esancol?

A: Regulatory information states that Esancol is contraindicated (not permitted) during the third trimester of pregnancy and is not recommended during the first and second trimesters. Official regulatory information should always be reviewed with a prescribing clinician.


Q: Can breastfeeding mothers use Esancol?

A: Regulatory guidelines indicate that the use of Esancol in breastfeeding mothers is restricted to short-term treatment only. This restriction is in place to manage the potential exposure of the active ingredients to the infant.


Q: What are the potential signs of an Esancol overdose?

A: Official overdose information generally states that symptoms may include severe forms of the common side effects, such as intense nausea, vomiting, and abdominal pain. If an overdose is suspected, contacting emergency medical services or a poison control center immediately is crucial.


Q: Can people with certain food allergies take Esancol?

A: Official regulatory documents list the inactive ingredients (excipients) used in Esancol preparations. Individuals with known food allergies should review this list with a pharmacist to ensure none of the inactive ingredients pose a risk.


Q: Does sun exposure need to be limited while taking Esancol?

A: Due to the potential for photosensitivity (increased sun sensitivity) from the sulfonamide component, regulatory warnings advise limiting exposure to sunlight and artificial UV light while undergoing treatment.


Q: Does Esancol interact badly with common pain relievers like ibuprofen?

A: Official product information for Esancol lists interactions with several drug classes, such as anticoagulants and antidiabetics. Specific warnings about common NSAID pain relievers like ibuprofen are not consistently documented in the primary regulatory warnings. Any potential systemic drug interaction should be reviewed by a prescribing clinician or pharmacist.


Q: Can Esancol be taken on an empty stomach?

A: Official guidelines specify that Esancol should be taken with food or shortly after a meal. This instruction is typically in place to manage absorption and potentially reduce gastrointestinal side effects. It is important to adhere to the official timing instructions provided with the medicine.


Q: Is it safe to take Esancol if I'm already on blood pressure medication?

A: While the official documentation for Esancol highlights specific interactions with anticoagulants and antidiabetic agents, it does not typically list warnings about blood pressure medication (antihypertensives) as a primary concern. It is important that all medications, including blood pressure drugs, be reviewed with a prescribing clinician or pharmacist.


Q: Are there any known long-term side effects from using Esancol?

A: Official regulatory reports are primarily based on studies conducted during the acute phase of illness, meaning the follow-up durations were short. Because of this, the long-term effects of the fixed-dose combination are not fully established in regulatory research.


Q: Why do doctors prescribe Esancol over other options?

A: Esancol is prescribed for its approved use as an intestinal anti-infective to fight susceptible pathogens directly in the gut. While the most substantial research relates to its single active ingredients, official documents note that comparative evidence for the fixed-dose combination against other single-agent treatments is limited.


Q: Is it normal to feel slightly nauseous when first starting Esancol?

A: Nausea is listed as one of the common adverse reactions reported in official regulatory documents for Esancol. Experiencing some nausea is therefore possible in patient populations. It is important to inform a healthcare professional if this or any other side effect persists or worsens.


Q: Does Esancol affect birth control pills?

A: Official regulatory warnings for Esancol focus on interactions with blood thinners and antidiabetic agents. There is no consistent, documented warning in the primary product information regarding a direct interaction with oral contraceptive pills (birth control pills).


Q: Does Esancol have different names in other countries?

A: Yes, it is common for a medicine, even with the same active ingredients, to be marketed under different brand names in various countries. International drug compendiums and global regulatory databases confirm that this medication, or its active ingredients, may be known by several different names worldwide.


Q: Is Esancol addictive or habit-forming?

A: Esancol is an antimicrobial agent intended to act locally in the digestive tract. It is not typically classified as a controlled substance, and regulatory information generally does not list any warnings regarding the medicine being addictive or habit-forming.


Q: Is it better to take Esancol in the morning or at night?

A: The official administration guidelines define a strict schedule of four times daily (QID) taken with food. As long as this regimen and the necessary time separation between doses are followed, the exact time of day is generally less critical than adhering to the required frequency.


Q: What types of drug interactions are most concerning with Esancol?

A: The official product information highlights several concerning systemic interactions. The most significant are with alcohol, which can cause a serious disulfiram-like reaction, and with oral anticoagulants (e.g., blood thinners) and certain oral antidiabetic agents, due to the risk of increased effects or side effects.


Q: Are there any warnings about combining Esancol with other common prescriptions?

A: Regulatory documents list specific warnings for several classes of prescription drugs, including oral anticoagulants, oral antidiabetic agents, and bile acid sequestrants (which require timing separation). Any other combination should be checked against a full drug interaction database by a health professional.

How should Esancol be stored and disposed of?

How to Store and Dispose of Esancol

Official regulatory documents define strict conditions for the storage and disposal of Esancol (Nifuroxazide/Phthalylsulfathiazole) to maintain product stability and safety.


Official Storage Requirements

  • Temperature and Environment: The product must be stored at controlled room temperature, typically below 25°C. It must be protected from moisture and direct light.
  • Packaging: Keep the medicine in its original container, and ensure the container is tightly closed when not in use.
  • Child Safety: All medication must be kept out of the sight and reach of children.
  • Stability: Do not use the medicine after the expiry date printed on the packaging.

Official Disposal Rules

Expired or unused Esancol must be disposed of according to local regulatory requirements. The preferred method is through an official drug take-back program or authorized collection site. The medicine must not be flushed or discarded into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Esancol found in:

A-Z Index: